JP2022503886A5 - - Google Patents
Info
- Publication number
- JP2022503886A5 JP2022503886A5 JP2021517575A JP2021517575A JP2022503886A5 JP 2022503886 A5 JP2022503886 A5 JP 2022503886A5 JP 2021517575 A JP2021517575 A JP 2021517575A JP 2021517575 A JP2021517575 A JP 2021517575A JP 2022503886 A5 JP2022503886 A5 JP 2022503886A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- antibody
- formulation
- pharmaceutical preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024098544A JP2024138284A (ja) | 2018-10-05 | 2024-06-19 | 抗ｆｇｆｒ２抗体製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862741772P | 2018-10-05 | 2018-10-05 | |
| US62/741,772 | 2018-10-05 | ||
| PCT/US2019/054684 WO2020072896A1 (en) | 2018-10-05 | 2019-10-04 | Anti-fgfr2 antibody formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024098544A Division JP2024138284A (ja) | 2018-10-05 | 2024-06-19 | 抗ｆｇｆｒ２抗体製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022503886A JP2022503886A (ja) | 2022-01-12 |
| JP2022503886A5 true JP2022503886A5 (enExample) | 2022-09-29 |
| JP7595567B2 JP7595567B2 (ja) | 2024-12-06 |
Family
ID=68343457
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517575A Active JP7595567B2 (ja) | 2018-10-05 | 2019-10-04 | 抗ｆｇｆｒ２抗体製剤 |
| JP2024098544A Pending JP2024138284A (ja) | 2018-10-05 | 2024-06-19 | 抗ｆｇｆｒ２抗体製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024098544A Pending JP2024138284A (ja) | 2018-10-05 | 2024-06-19 | 抗ｆｇｆｒ２抗体製剤 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20220010020A1 (enExample) |
| EP (1) | EP3860563A1 (enExample) |
| JP (2) | JP7595567B2 (enExample) |
| KR (1) | KR20210074286A (enExample) |
| CN (1) | CN112804989A (enExample) |
| AU (1) | AU2019355995B2 (enExample) |
| BR (1) | BR112021005204A2 (enExample) |
| CA (1) | CA3112215A1 (enExample) |
| CO (1) | CO2021004985A2 (enExample) |
| CR (1) | CR20210217A (enExample) |
| EA (1) | EA202190878A1 (enExample) |
| EC (1) | ECSP21031139A (enExample) |
| IL (1) | IL281976A (enExample) |
| MX (1) | MX2021003766A (enExample) |
| MY (1) | MY208925A (enExample) |
| PE (1) | PE20211213A1 (enExample) |
| PH (1) | PH12021550670A1 (enExample) |
| SG (1) | SG11202102875YA (enExample) |
| UA (1) | UA130250C2 (enExample) |
| WO (1) | WO2020072896A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| JP2024501565A (ja) * | 2020-12-29 | 2024-01-12 | 深▲せん▼福沃薬業有限公司 | 抗ｆｇｆｒ２抗体およびその使用 |
| TW202342527A (zh) * | 2022-02-25 | 2023-11-01 | 美商安進公司 | 鱗狀非小細胞肺癌之治療 |
| CN119110806A (zh) * | 2022-03-28 | 2024-12-10 | 杭州中美华东制药有限公司 | 新型抗fgfr2抗体 |
| CN121039158A (zh) * | 2023-03-31 | 2025-11-28 | 杭州中美华东制药有限公司 | 新型抗fgfr2抗体 |
| WO2025067442A1 (zh) * | 2023-09-28 | 2025-04-03 | 南京维立志博生物科技股份有限公司 | 抗fgfr2抗体和包含其的多特异性结合分子 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| ES2244066T3 (es) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | Procedimiento y composiciones de glicoproteinas galactosiladas. |
| AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING A POLYPEPTIDE |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| NZ571596A (en) | 2001-08-03 | 2010-11-26 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| CA2463879C (en) | 2001-10-25 | 2012-12-04 | Genentech, Inc. | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING ANTIBODY COMPOSITION |
| BR0309145A (pt) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Células das quais o genoma é modificado |
| CA2481925A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for patients having human fc.gamma.riiia |
| ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| CA2481658A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to fcy receptor iiia |
| EP1500400A4 (en) | 2002-04-09 | 2006-10-11 | Kyowa Hakko Kogyo Kk | MEDICAMENT WITH ANTIBODY COMPOSITION |
| TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
| JPWO2005035586A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
| JPWO2005035778A1 (ja) | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法 |
| US9296820B2 (en) | 2003-11-05 | 2016-03-29 | Roche Glycart Ag | Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| AU2008208288B2 (en) | 2007-01-24 | 2014-04-03 | Kyowa Kirin Co., Ltd. | Genetically recombinant antibody composition having enhanced effector activity |
| HUE035700T2 (en) | 2008-11-07 | 2018-05-28 | Galaxy Biotech Llc | Monoclonal antibodies to Fibroblast Growth Factor receptor 2 |
| KR102516152B1 (ko) | 2013-08-01 | 2023-03-31 | 파이브 프라임 테라퓨틱스, 인크. | 비푸코실화된 항-ｆｇｆｒ２ｉｉｉｂ 항체 |
| MX2018006181A (es) | 2015-11-23 | 2018-09-24 | Five Prime Therapeutics Inc | Inhibidores de fgfr2 solos o en combinacion con agentes que estimulan el sistema inmunitario en el tratamiento contra el cancer. |
-
2019
- 2019-10-04 PE PE2021000414A patent/PE20211213A1/es unknown
- 2019-10-04 SG SG11202102875YA patent/SG11202102875YA/en unknown
- 2019-10-04 CN CN201980064961.XA patent/CN112804989A/zh active Pending
- 2019-10-04 MX MX2021003766A patent/MX2021003766A/es unknown
- 2019-10-04 JP JP2021517575A patent/JP7595567B2/ja active Active
- 2019-10-04 US US17/282,589 patent/US20220010020A1/en active Pending
- 2019-10-04 AU AU2019355995A patent/AU2019355995B2/en active Active
- 2019-10-04 UA UAA202102307A patent/UA130250C2/uk unknown
- 2019-10-04 KR KR1020217009515A patent/KR20210074286A/ko not_active Ceased
- 2019-10-04 BR BR112021005204-6A patent/BR112021005204A2/pt unknown
- 2019-10-04 EP EP19794304.6A patent/EP3860563A1/en active Pending
- 2019-10-04 EA EA202190878A patent/EA202190878A1/ru unknown
- 2019-10-04 MY MYPI2021001632A patent/MY208925A/en unknown
- 2019-10-04 WO PCT/US2019/054684 patent/WO2020072896A1/en not_active Ceased
- 2019-10-04 CA CA3112215A patent/CA3112215A1/en active Pending
- 2019-10-04 CR CR20210217A patent/CR20210217A/es unknown
-
2021
- 2021-03-25 PH PH12021550670A patent/PH12021550670A1/en unknown
- 2021-04-01 IL IL281976A patent/IL281976A/en unknown
- 2021-04-19 CO CONC2021/0004985A patent/CO2021004985A2/es unknown
- 2021-05-03 EC ECSENADI202131139A patent/ECSP21031139A/es unknown
-
2024
- 2024-06-19 JP JP2024098544A patent/JP2024138284A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022503886A5 (enExample) | ||
| US20260001965A1 (en) | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii | |
| JP7046088B2 (ja) | 抗ｒｓｖモノクローナル抗体製剤 | |
| US20230355758A1 (en) | Pharmaceutical Formulations | |
| US20220251210A1 (en) | Formulation comprising anti-cd47/pd-l1 bispecific antibody, method for preparing same and use thereof | |
| AU2015342815A1 (en) | Stable protein solution formulation containing high concentration of an anti-VEGF antibody | |
| JP2008520551A5 (enExample) | ||
| TW201806617A (zh) | 穩定之液體醫藥調配物 | |
| JP2022036932A5 (enExample) | ||
| JP2014526559A (ja) | 悪液質治療 | |
| TW202222823A (zh) | 投與治療劑量的雙特異性ｔ細胞接合分子治療癌症之方法 | |
| EP4683941A1 (en) | Combination of antibodies, or antigen-binding fragments thereof, for the treatment of cancer and composition thereof | |
| JP2024540435A5 (enExample) | ||
| CN111683681B (zh) | 包含抗ox40抗体的制剂、其制备方法及其用途 | |
| JP2023546504A5 (enExample) | ||
| US20210198382A1 (en) | Novel monoclonal antibody having anti-inflammatory action | |
| JP2024505923A5 (enExample) | ||
| TWI886758B (zh) | 抗pvrig/抗tigit雙特異性抗體在治療惡性腫瘤中的用途 | |
| CN116688115B (zh) | 一种PD-L1/TGF-β双功能融合蛋白制剂及其用途 | |
| US20250255818A1 (en) | Lyophilization method | |
| US20260125464A1 (en) | Methods of treating cachexia | |
| US20260062500A1 (en) | Bispecific antibody targeting hk2 and cd3 for the treatment of prostate cancer | |
| JP2019505516A (ja) | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 | |
| TW202541845A (zh) | 穩定醫藥製劑 | |
| CA2966758C (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody |